AstraZeneca's $4 billion Acerta deal endorsed by orphan drug status

LONDON (Reuters) - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro